Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited

NNASDAQ:ZYBT
1.43
USD
-0.07
(-4.67%)
54.50MMarket Cap
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
(Nasdaq Stock Market)

Recent

price

1.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
CNY
4.69
5.7
4.63
3.95
2.46
- -
Revenue per Share
0.85
1.02
0.69
0.24
-1.47
- -
Basic EPS, GAAP
0.12
-0.22
0.8
0.28
0.01
- -
Free Cash Flow per Basic Share
0.24
0.47
0.86
0.34
- -
- -
Dividend per Share
5.67
6.29
5.78
6.02
5.27
5.27
Book Value per Share
5.23
5.69
5.27
5.54
4.12
4.12
Tangible Book Value per Share
46
46
46
47
47
47
Basic Weighted Avg Shares
214
260
212
186
116
- -
Sales/Revenue/Turnover
25.98
25.39
22.51
9.21
-58.66
- -
Operating Margin (%)
16
19
24
24
26
- -
Depreciation Expense
39
47
31
11
-70
- -
Net Income, GAAP
12.44
12.79
14.29
6.42
- -
- -
Effective Tax Rate (%)
18.2
17.96
14.86
6.07
-59.97
- -
Profit Margin (%)
39
62
39
42
17
17
Working Capital
- -
10
10
5
9
9
LT Debt
319
357
339
353
307
307
Total Equity
- -
15.4
9.37
3.68
- -
- -
Return on Invested Capital (%)
- -
10.43
6.86
2.98
- -
- -
Return on Capital (%)
- -
16.57
11.05
4.06
-26.15
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
82
81
66
LT Borrowings
5
5
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
- -
2,027
381

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
178
201
137
Cash, Cash Equivalents & STI
20
48
52
Accounts Receivable, Net
60
37
18
Inventories
58
54
39
Total Current Liabilities
136
135
120
Payables & Accruals
47
47
49
ST Debt
82
81
66
Deferred Revenue
4
6
5

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-13%
Free Cash Flow
- -
- -
-94.7%
Net Income, GAAP
- -
- -
-716.96%
Sales/Revenue/Turnover
- -
- -
-37.56%
Total Cash Common Dividend
- -
- -
-100%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
212
2024
- -
- -
186
2025
- -
- -
116

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.69
2024
- -
- -
0.24
2025
- -
- -
-1.47

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.86
2024
- -
- -
0.34
2025
- -
- -
- -
Business
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines with a primary focus on livestock including swine, cattle, goats, sheep, poultry, and dogs. Its product portfolio comprises approximately 46 veterinary vaccines covering monovalent, polyvalent, combined, and combined and polyvalent vaccines. The company operates three GMP veterinary vaccine production floors with 13 production lines, a quality examination center, and an animal facility dedicated to vaccine development. Zhengye markets its products across 28 provincial regions in China and exports internationally to Vietnam, Pakistan, and Egypt. Founded in 2004 and headquartered in Jilin, China, the company serves livestock farmers, local governments, domestic distributors, and exporting distributors. In the last two years, Zhengye completed a successful Nasdaq initial public offering in January 2025, raising approximately $6.9 million to support expansion. Strategic shifts include reducing reliance on swine vaccines to diversify its customer base and accelerate growth in the pet vaccine segment, marked by completed clinical trials for cat and dog vaccines. The company also received two Category I New Veterinary Drug Certificates from the Ministry of Agriculture and Rural Affairs for vaccines developed jointly with academic and industry partners, granting market exclusivity and reinforcing its R&D capabilities. Zhengye continues to invest in expanding global distribution and manufacturing capacity, positioning itself for growth in both domestic and international veterinary vaccine markets. It operates as a subsidiary of Securingium Holding Limited.

Company News

  • Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

  • Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

  • Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

  • Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  • Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  • Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

  • Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

  • Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Declines By 36.7%

  • Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

  • Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

  • Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

  • Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

  • U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

  • Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

  • Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

  • Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO